Benefits
PDE5 Inhibition: A Laboratory Mechanism, Not a Proven Effect
Icariin selectively inhibits phosphodiesterase-5 (PDE5) — same target as sildenafil (Viagra), tadalafil (Cialis), vardenafil. In laboratory testing icariin is roughly 80 times weaker than sildenafil. No human trial cited on this page shows that this translates into better erections; the 2022 review linked here describes the erectile benefit as unconfirmed and calls for clinical research with high quality and large samples.
Bone Health (Osteoporosis)
This is the strongest part of the evidence, with one large caveat. The 24 month randomized, double blind, placebo controlled trial cited on this page (100 women enrolled, 85 completed, all late postmenopausal with borderline low bone density) tested a combination capsule: 60 mg icariin plus 15 mg daidzein, 3 mg genistein and 300 mg calcium per day. Lumbar spine bone density rose 1.3% on treatment while the placebo group lost 2.4% (p=0.006), and a bone breakdown marker fell 39 to 43%. Soy isoflavones and calcium both act on bone on their own, so the result cannot be credited to epimedium alone. A separate 2021 double blind trial of Epimedium prenylflavonoids in postmenopausal women measured bone turnover markers, not bone density or fractures. All of this was studied in postmenopausal women already losing bone, and it is not evidence that the herb prevents or treats osteoporosis in a healthy person.
Sexual Function and Libido
TCM use for sexual function is centuries old. Modern human evidence is thin. The only sexual function source cited on this page is a 2022 narrative review that examines the molecular mechanism, treats the erectile benefit as an unconfirmed myth, and asks for high quality clinical trials with large samples. No placebo controlled human trial of epimedium for libido, erectile function or sexual satisfaction is cited here.
Estrogen-Like Effects (Bone, Menopause)
In laboratory work icariin shows weak estrogen like activity, which is the proposed reason for interest in bone and menopause. This is a cell and animal level mechanism; no human trial cited here measured menopausal symptoms, and icariin is weaker than soy isoflavones.
Anti-Inflammatory and Neuroprotective Research
Animal models show neuroprotection, anti-inflammatory, and modest cognitive effects. Human translation limited.
Mechanism of action
PDE5 Inhibition
Icariin competitively inhibits PDE5 enzyme — preventing degradation of cGMP in penile vasculature. More cGMP means more blood vessel relaxation, which is the proposed route to a better erectile response. That chain has been shown in laboratory and animal work only; icariin is about 80 times weaker than sildenafil, and the human step has not been demonstrated in anything cited on this page.
Estrogen Receptor Activation (Weak)
Icariin binds estrogen receptors weakly in laboratory studies, which is the proposed basis for effects on bone; effects on menopausal symptoms have not been tested in the human trials cited here. Distinct from steroidal phytoestrogens; flavonoid structure.
Testosterone Effects (Disputed)
Some animal studies suggest mild testosterone-supportive effects via testicular steroidogenesis. Human evidence inconsistent. Not reliable testosterone-booster.
Bone-Forming Cell (Osteoblast) Stimulation
Animal and cell culture evidence: icariin stimulates osteoblast differentiation and reduces osteoclast activity. Basis for osteoporosis applications.
Clinical trials
The link goes to a 2022 narrative review in Translational Andrology and Urology titled 'Deciphering the myth of icariin and synthetic derivatives in improving erectile function'. It is a discussion of molecular mechanisms, not a clinical trial, and it does not appear in the reference list below.
None. No participants were enrolled; this is a review of mostly laboratory and animal research.
The review does not establish that icariin improves erectile function in people; it concludes that more clinical and basic research with high quality and large samples is needed. There is no placebo comparison here because there was no trial. Erectile difficulties are a medical issue worth discussing with a doctor rather than self-treating with a supplement.
One 24 month randomized, double blind, placebo controlled trial (Journal of Bone and Mineral Research, 2007). The tested capsule was a combination: 60 mg icariin plus 15 mg daidzein, 3 mg genistein and 300 mg calcium per day. It is currently linked but not listed in the reference list below.
100 late postmenopausal women with a lumbar spine T score between -2 and -2.5 were enrolled; 85 completed the full two years.
Lumbar spine bone density rose 1.3% over 24 months on the combination while the placebo group lost 2.4% (p=0.006), and the bone breakdown marker deoxypyridinoline fell 39 to 43%. A two year placebo controlled trial is unusually long and this is real evidence, but because the capsule also contained soy isoflavones and calcium, both of which affect bone on their own, the benefit cannot be attributed to epimedium by itself. The women studied were already losing bone, so this does not describe what the herb does for a healthy adult.